logo
  Join        Login             Stock Quote

Mylan (MYL) Gets Approval For Generic Pulmonary Arterial Hypertension Drug

 June 06, 2012 08:14 AM
 


(By Balaseshan) Mylan Inc. (NASDAQ:MYL), a pharmaceutical company, said its subsidiary received Health Canada approval for generic version of Actelion Pharmaceuticals Ltd.'s pulmonary arterial hypertension drug Tracleer.

Mylan Pharmaceuticals ULC has received approval from Health Canada for Mylan-Bosentan Tablets, 62.5 mg and 125 mg. Mylan-Bosentan is the generic version of Actelion's Tracleer, used for the treatment of pulmonary arterial hypertension.

Pulmonary arterial hypertension is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual. The function of the heart and lungs is severely compromised, manifested by a limited exercise capacity, and, ultimately, a reduced life expectancy.

[Related -Mylan, Inc. (MYL) Q3 Earnings Preview: Weak Dollar = Strong Profit?]

The first signs of the disease, such as mild shortness of breath, fatigue and difficulty exercising, are so subtle that the disease is often either misdiagnosed or not diagnosed until the patient's condition is far advanced. The survival rate for pulmonary arterial hypertension in untreated patients is only 40% to 55% at two years from the onset of symptoms.

Once patients reach more advanced stages of pulmonary arterial hypertension, they often have no choice but to go on prostacyclin therapy, which requires a 24-hour infusion pump and an intravenous line implanted through the chest directly into the patient's heart. Ultimately, many patients require lung transplantation.

[Related -Mylan Inc (MYL): Patent Cliff Set To Fuel 200% Gain]

According to IMS Health, Bosentan Tablets had Canadian sales of about $37.8 million for the twelve months ending March 31, 2012. In Canada, generic drugs cost consumers an average of 60% less than their brand name counterparts.

Currently, Mylan Canada has 38 product applications pending Health Canada approval. These 38 products represent $2.6 billion in annual sales for the 12 months ending March 31, 2012, according to IMS Health.

MYL closed Tuesday's regular session up 0.41% at $20.99. The stock has been trading between $15.49 and $25 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.